39th week of 2021 patent applcation highlights part 10 |
Patent application number | Title | Published |
20210299116 | METHODS FOR REDUCING ABNORMAL SCAR FORMATION - This disclosure is directed to methods of reducing scar collagen abundance, scar width, and scar tissue contracture comprising administering to a subject in need of such treatment an effective amount of a mast cell stabilizer, or an effective amount of a HIF prolyl hydroxylase domain inhibitor, or an effective amount of a combination of a mast cell stabilizer and a HIF prolyl hydroxylase domain inhibitor. | 2021-09-30 |
20210299117 | SMAD3 Inhibitors - Smad3 inhibitor compounds, specifically a compound of Formula 1 or Formula 2, or a pharmaceutically acceptable salt thereof, and its use in treating or preventing cell proliferation or cancer in a subject are provided. | 2021-09-30 |
20210299118 | Coordinated Metabolic Reprogramming in Response to Productive Viral Infections - The invention generally relates to methods of treating viral infections using known drugs and pharmaceutical compositions comprising same. More specifically, the disclosed methods are useful for the treatment of viral infections that are enveloped viruses. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2021-09-30 |
20210299119 | Methods Of Providing Weight Loss Therapy In Patients With Major Depression - Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression. | 2021-09-30 |
20210299120 | QUINOLINE DERIVATIVES WITH OTHER ANTI-VIRAL AGENTS - Compositions and methods for the treatment or prophylaxis of viral and other infections (e.g., coronavirus) are provided. The compositions typically comprise a quinoline derivative and an additional anti-viral agent. Incorporations of these agents into fabrics for use as filtration devices which forestall infection is also disclosed. | 2021-09-30 |
20210299121 | CETIRIZINE OPHTHALMIC COMPOSITIONS - The present invention relates to an ophthalmic composition comprising cetirizine and one or more pharmaceutically acceptable excipients, wherein said composition is free of benzalkonium chloride and/or dibasic sodium phosphate. The invention particularly relates to a 0.24% cetirizine ophthalmic composition, wherein said composition is free of benzalkonium chloride and/or dibasic sodium phosphate. Further, the invention may also provide a process of preparing such composition and their use for treating allergic conjunctivitis and/or allergic rhinoconjunctivitis. | 2021-09-30 |
20210299122 | METHODS AND COMPOSITIONS FOR TREATING DIABETES, METABOLIC SYNDROME AND OTHER CONDITIONS - Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma. | 2021-09-30 |
20210299123 | SURVIVIN-TARGETING ANTI-TUMOR AGENTS AND USES THEREOF - Methods for treating various cancers by administering one or more compounds that target the dimeric protein survivin are disclosed. Pharmaceutical compositions containing such compounds are also disclosed, along with general methods of identifying anti-cancer compounds that target oncogenic dimeric proteins. Exemplary compounds that can be used in the disclosed methods of treatment and pharmaceutical compositions have the chemical structures disclosed in the specification. | 2021-09-30 |
20210299124 | METHODS - The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease. | 2021-09-30 |
20210299125 | CERDULATINIB FOR TREATING MYELOMA - Compositions and methods for treating multiple myeloma (MM), acute myeloid lymphoma (AML) or a myeloproliferative disease (MPD) in a human patient in need thereof. The methods entail administering to the patient an effective amount of cerdulatinib. | 2021-09-30 |
20210299126 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE - The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases. | 2021-09-30 |
20210299127 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NONALCOHOLIC STEATOHEPATITIS - The present invention relates to a medical use of a compound, of Chemical Formula 1, for treating, alleviating or preventing non-alcoholic steatohepatitis (NASH) and/or hepatic fibrosis. | 2021-09-30 |
20210299128 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA - This invention relates to compounds for treating acute myeloid leukemia or inhibiting recurrence of acute myeloid leukemia and for inhibiting growth of and/or killing leukemic stem cells. | 2021-09-30 |
20210299129 | Cardiosafe Antidiabetic Therapy - The present invention relates to methods of using DPP-4 inhibitors, optionally in combination with one or more other active agents, for cardio-safe antidiabetic therapy. | 2021-09-30 |
20210299130 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY - This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders. | 2021-09-30 |
20210299131 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH - Methods for enhancing memory and/or learning and prevent neurodegeneration by administration of certain heterocyclic and aromatic compounds are described. The methods are particularly useful for treating patients suffering from a neurodegenerative disease such as (without limitation) Alzheimer's, Parkinsons's, Lou Gehrig's (ALS) disease or memory or learning impairment. A neuronal human cell-based assay that assess NF-kB gene up-regulation using a luciferase reporter is also provided that screens for compounds useful in methods for enhancing memory or learning. | 2021-09-30 |
20210299132 | Platelet Count-Agnostic Methods of Treating Myelofibrosis - Reanalysis of the SIMPLIFY 1 and 2 trials data indicates MMB is effective in JAKi-naïve patients and in second line therapy to RUX, providing benefits of reducing enlarged spleens, improving myelofibrosis-related symptoms, and increasing transfusion independence in patient at risk for thrombocytopenia from the underlying disease and RUX therapy. Accordingly, methods of treating myeloproliferative neoplasms (MPN) such as myelofibrosis are described. The methods can include administering a therapeutically effective amount of momelotinib or a pharmaceutically acceptable salt thereof to a subject identified as having (i) myelofibrosis and (ii) a platelet count of less than 150×10 | 2021-09-30 |
20210299133 | TREATMENT OF SQUAMOUS CELL CARCINOMA - The present invention relates to a method of predicting the vulnerability of a squamous cell carcinoma (SCC) to inhibition by a P13K inhibitor, preferably by a P13K/mTOR inhibitor, including the selection of the patient predicted to benefit from therapeutic administration with the P13K inhibitor, preferably of the P13K/mTOR inhibitor. Moreover, the present invention relates to a method of treating a squamous cell carcinoma (SCC) of a mammal, preferably a human patient, comprising administering a therapeutically effective amount of a P13K inhibitor, preferably a therapeutically effective amount of a P13K/mTOR inhibitor to said mammal, preferably said human patient. Furthermore, the present invention relates to pharmaceutical compositions and kits associated with the inventive methods. | 2021-09-30 |
20210299134 | TREATMENT OF B CELL MALIGNANCIES - Provided herein are methods of treating cancer using a phosphoinositide-3-kinase (PI3K) inhibitor. In certain embodiments, the cancer is follicular lymphoma (FL). In certain embodiments, the PI3K inhibitor is administered on a continuous dosing schedule (CS). In other embodiments, the PI3K inhibitor is administered on an intermittent dosing schedule (IS). | 2021-09-30 |
20210299135 | METHODS FOR THE TREATMENT OF PSORIATIC ARTHRITIS - The present invention relates to compound according to Formula I: | 2021-09-30 |
20210299136 | Compositions And Methods For Inhibiting Type 1 Collagen Production - This discloses that compounds of Formula 1 may be used as antifibrotics because they inhibit type 1 collagen production. In particular, this discloses a pharmaceutical composition containing one or more compounds of Formula 1 and methods of using compounds of Formula 1 in fibrosis treatment and inhibiting type 1 collagen synthesis. | 2021-09-30 |
20210299137 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES - Compounds for treatment of diseases having acidic or hypoxic diseased tissues and pharmaceutical compositions comprising the compounds, as well as methods for making and using the compounds and compositions. | 2021-09-30 |
20210299138 | Treating Hearing Loss - This invention relates to methods for treating hearing loss associated with loss of cochlear hair cells, e.g., caused by noise exposure, using certain gamma secretase inhibitors, in post-neonatal animals, e.g., adolescents and adults. | 2021-09-30 |
20210299140 | METHODS OF TREATING PROTEINOPATHY-ASSOCIATED WANDERING - The invention is based on the discovery that rho kinase inhibitors can be used to treat proteinopathy associated wandering. A number of degenerative neurological diseases are thought to be caused, at least in part, by the formation of protein aggregates that cause neurotoxicity and progressive decline in function. The inventive methods related to the use of rho kinase inhibitors in the treatment of patients with proteinopathy-associated wandering. The patients may be suffering from Huntington's disease, a traumatic brain injury, autism spectrum disorder, Down syndrome or a proteinopathy-associated dementia, such as Alzheimer disease or frontotemporal dementia. | 2021-09-30 |
20210299141 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS - The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases. | 2021-09-30 |
20210299142 | Use of Medications with Neuroprotective Properties to Prevent or Reduce the Risk of Ischemia-Reperfusion Injury in a Subject - Provided are methods for treatment and prevention of ischemia-reperfusion injury and chronic intermittent hypoxia related injury through administering a neuroprotective compound. A subject benefiting from the method of the invention may be prescribed or undergoing anti-VEGF treatment, for example an IVAV treatment regimen, or may be diagnosed with a disorder such as sleep apnea. | 2021-09-30 |
20210299143 | USE OF ANTAGONISTS TO THE NUCLEAR STEROID RECEPTOR TO INHIBIT CORONAVIRUSES - Compositions including at least one nuclear steroid family (NSF) receptor antagonist for the treatment or prevention of a coronavirus infection, such as SARS-CoV-2, and for the treatment of symptoms resulting from such infection. Also provided herein are methods of administering such compounds to a patient, either in a combination pharmaceutical formulation or in separate pharmaceutical formulations, to treat or prevent viral infections, including viral infections from coronaviruses such as SARS-CoV-2. Treatment decreases a viral load in a subject and/or may ameliorate symptoms associated with or produced by viral infection. Various administration modalities and mechanisms may be selected depending upon a condition of a patient and the patient's ability to be administered via a selected modality. | 2021-09-30 |
20210299144 | USE OF PREGNENOLONE SULFATE TO REDUCE CYST FORMATION IN KIDNEY - A method for the treatment or the prevention of a kidney disorder is disclosed. The method involves administering an effective concentration of pregnenolone sulfate to a subject to increase cytoplasmic Ca | 2021-09-30 |
20210299145 | 17A-MONOESTERS AND 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS - The present invention relates to certain cortexolone derivatives of formula (I) | 2021-09-30 |
20210299146 | SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use. | 2021-09-30 |
20210299147 | SLEEP AID AND RELATED METHODS - A stable composition suitable for use as a sleep aid is described. The composition has, in combination: cannabinol, melatonin, magnesium glycinate, menaquinone, cholecalciferol, calcium, Vitamin E, L-Tryptophan, and gamma-aminobutyric acid. | 2021-09-30 |
20210299148 | FLUORINATED BILE ACID DERIVATIVES - The invention relates to compounds of general formula (I): | 2021-09-30 |
20210299149 | METHODS AND COMPOSITIONS FOR TREATING MEIBOMIAN GLAND DYSFUNCTION - The invention provides methods, compositions, and kits containing a minocycline topical suspension, for treating meibomian gland dysfunction and related disorders. | 2021-09-30 |
20210299150 | AP39 IMPACT ON MITOCHONDRIA, METABOLISM, GENE TRANSCRIPTION REGULATION, CARDIOTOXICITY PROTECTION AND CANCER TREATMENT - A method of predicting and treating doxorubicin-resistant cancer including determining expression of Myc-regulated genes and MPST transcription levels. The method further includes classifying the cancer as doxorubicin resistant when either Myc transcription is higher than IMR-32 transcription or MPST transcription levels are above a predetermined amount. The method further includes administering an effective amount of AP39 for ameliorating the doxorubicin-induced cardiotoxicity by combing doxorubicin with AP39. | 2021-09-30 |
20210299151 | TOPICAL, ISOTONIC COMPOSITIONS FOR GENITAL USE - The present disclosure provides compositions and methods for using topical, isotonic compositions comprising a prebiotic oligosaccharide, a metal co-factor, and an essential oil comprising bornyl acetate. The compositions support the genital microbiota and are useful for, for example, hydrating, lubricating, cleaning, and/or decreasing irritation or inflammation of the urogenital and/or anogenital region of a subject, and/or enhancing the beneficial genital microbiota of a subject. Such compositions are useful before, during, and/or after sexual and/or reproductive activity. | 2021-09-30 |
20210299152 | ORAL COMPOSITIONS AND METHODS FOR AFFECTING MAMMALIAN OFFSPRING - The present invention discloses methods and compositions for nourishing newly-borne mammals; specifically, reducing antibiotic usage, increasing weight and increasing immunoglobulin concentrations in said newly borne mammals, following oral treatment of pregnant mammals of said newly-borne mammals. The compositions of the current invention have chicken, beef, fish or apple flavouring. | 2021-09-30 |
20210299153 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD). | 2021-09-30 |
20210299154 | Senolytic Compositions And Uses Thereof - Provided herein are senolytic agents for selectively killing senescent cells that are associated with numerous pathologies and diseases, including age-related pathologies and diseases. As disclosed herein, senescent cell-associated diseases and disorders may be treated or prevented by administering at least one senolytic agent or pharmaceutical compositions thereof. The senescent cell-associated diseases or disorders treated or prevented by the methods described herein include, but are not limited to, cardiovascular diseases or disorders, cardiovascular diseases and disorders associated with arteriosclerosis, such as atherosclerosis, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), osteoarthritis, inflammatory diseases or disorders, autoimmune diseases or disorders, pulmonary diseases or disorders, neurological diseases or disorders, dermatological diseases or disorders, chemotherapeutic side effects, radiotherapy side effects, metastasis and metabolic diseases. | 2021-09-30 |
20210299155 | METHODS OF MODULATING IMMUNE ACTIVITY - In one aspect, the invention provides methods of increasing immune response by administering posteellular signaling factors produced by cells exposed to a stress condition. In one aspect, the invention provides methods of increasing immune response by administering in combination (a) a Stimulator of Interferon Genes (STING) agonist and (b) a purinergic receptor agonist. The increase in immune response may be used, for example, for treatment of infection or cancer. The invention also provides screening assays for identification of compounds that induce production of postcellular signaling factors which are also immunostimulatory agents. The invention further provides methods for identifying postcellular signaling factors with immunostimulatory activity. In another aspect, the invention provides methods of decreasing immune response by administering to a cell, tissue or subject a purinergic receptor antagonist alone or in combination with a Stimulator of Interferon Genes (STING) antagonist. | 2021-09-30 |
20210299156 | METHODS OF INHIBITING OR TREATING CORONAVIRUS INFECTION, AND METHODS FOR DELIVERING AN ANTI-NUCLEOLIN AGENT - A method of administering an anti-nucleolin agent to a patient by delivering the anti-nucleolin agent to the mouth, lungs, throat, nose and eyes of a patient to prevent COVID-19. Compositions for administering an anti-nucleolin agent comprising a container and a formulation including an anti-nucleolin agent. The anti-nucleolin agent may be administered via an inhaler, nasal spray or eye drop. | 2021-09-30 |
20210299157 | CELLULOSE-BASED TOPICAL FORMULATIONS - The technology concerns topical formulations including nanocellulose materials for application on a skin or tissue of a subject. | 2021-09-30 |
20210299158 | Heparin Conjugated to Collagen-Binding Peptides for Targeting to Biological and Synthetic Tissues - Disclosed are heparin conjugates comprising heparin conjugated to a peptide that binds to a protein of the extracellular matrix (ECM) of cellular tissue, such as a collagen-binding peptide that binds to collagen of the ECM. The disclosed heparin conjugates may be utilized in methods that include treating ECM material to incorporate the heparin conjugates and impart anticoagulant activity to the ECM. The disclosed heparin conjugates also may be formulated as pharmaceutical compositions for treating and/or preventing vascular injuries and conditions. | 2021-09-30 |
20210299159 | LOW ENDOTOXIN FU CAN COMPOSITIONS, SYSTEMS AND METHODS - Low endotoxin fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising less than about 0.2, 0.18, 0.1, 0.01, 0.001, or 0.0005 endotoxin units (EU) per milligram of the fucan are disclosed. Methods and systems for removing or reducing the amount of endotoxins from a starting fucan composition are also disclosed. | 2021-09-30 |
20210299160 | COMBINATION THERAPIES THAT ENHANCE ANTIMICROBIAL/ANTICANCER ACTIVITIES - Techniques regarding a chemical composition that can be utilized within one or more combination therapies to treat a microbial infection are provided. For example, one or more embodiments described herein can comprise a chemical composition that includes a first triblock polymer comprising a quaternary ammonium functionalized polycarbonate block and exhibiting anticancer activity via a lytic mechanism. The chemical composition can also include a second triblock polymer comprising a guanidinium functionalized polycarbonate block and exhibiting anticancer activity via a translocation mechanism. | 2021-09-30 |
20210299161 | THERAPUETIC HYDROGEN GAS GENERATION AND DELIVERY - For hydrogen generation and delivery, a hydrogen source provides hydrogen. A delivery tube delivers the hydrogen from the hydrogen source for inhalation. A hydrogen sensor measures hydrogen concentration in the delivery tube. A controller adjusts the hydrogen concentration in the delivery tube to a concentration threshold. | 2021-09-30 |
20210299162 | MOLECULAR HYDROGEN-CONTAINING COMPOSITION FOR PREVENTION AND/OR IMPROVEMENT OF ENCEPHALITIS AND/OR MENINGITIS AND SYMPTOM ASSOCIATED WITH THE ENCEPHALITIS AND/OR MENINGITIS - The present invention provides a composition for prevention and/or improvement of encephalitis and/or meningitis. More specifically, the present invention provides a composition for prevention and/or improvement of encephalitis and/or meningitis and a symptom associated with the encephalitis and/or meningitis in a subject, comprising molecular hydrogen as an active ingredient. | 2021-09-30 |
20210299163 | THERAPY OF HIGH-RISK HUMAN PAPILLOMAVIRUS INFECTIONS - The present invention provides a pharmaceutical composition containing a selenite-containing compound and a pharmaceutically acceptable acid, selected from citric acid, acetic acid, malic acid, carbonic acid, sulfuric acid, nitric acid, hydrochloric acid, fruit acids and mixtures thereof. This composition is for use in the prevention or treatment of an infection of an internal reproductive organ of a female patient with at least one human papillomavirus (HPV) selected from HPV16, HPV18, HPV31, HPV33 and HPV58. The composition is applied intravaginally. | 2021-09-30 |
20210299164 | COMPOSITION OF CARBON DIOXIDE ABSORBENT OR ADSORBENT, WHEREBY THE SAID COMPOSITION CONTAINS A POLYMERIC COATING SELECTED FROM SILICONE RUBBER AND CELLULOSE DERIVATIVE - Disclosed is a composition of 10 wt % to 99 wt % of carbon dioxide absorbent or adsorbent, wherein the carbon dioxide absorbent or adsorbent is selected from the group consisting of inorganic hydroxides of alkali hydroxides and/or alkaline earth metal hydroxides, molecular sieves, zeolites, zinc (ii) ions, deep eutectic solvents and/or silica, whereby the composition contains 1 wt % to 90 wt %, relative to the total composition, of a polymeric coating selected from the group consisting of silicone rubber obtained from liquid silicone rubber and cellulose derivative for use in medicine for the prophylaxis and treatment of respiratory diseases in a mammal. | 2021-09-30 |
20210299165 | AMORPHOUS CALCIUM CARBONATE FOR TREATING A LEUKEMIA - The present invention provides compositions and methods of treating a leukemia, including chronic lymphocytic leukemia, wherein the method comprises administering a stabilized amorphous calcium carbonate to a person in need thereof. | 2021-09-30 |
20210299167 | STABLE IODINE-CONTAINING ANTIMICROBIAL TEAT DIP COMPOSITIONS - The germicidal aqueous teat dip compositions contain a stabilizing amount of a EO-PO copolymer composition and an antimicrobial effective amount of iodine. The iodine-based teat dip compositions can be used to reduce the incidence of contagious and environmental mastitis in dairy heads. The compositions can be applied to udder and teats of dairy herds to form a protective coating that can prevent infection from | 2021-09-30 |
20210299168 | PHARMACEUTICAL-GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME - The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels. | 2021-09-30 |
20210299169 | Galectin-3 Governs and Coordinates ESCRT and Autophagic Responses During Endomembrane Damage - The present invention is directed to the discovery that Galectin-3 (Gal3) governs and coordinates ESCRT and autophagic responses in subjects and that compositions and methods of treatment can make use of this discovery in the treatment of autophagy mediated disease states and/or conditions. | 2021-09-30 |
20210299170 | METHOD FOR IMPROVING ANTICANCER AGENT EFFICACY - The present invention relates to a method for improving the therapeutic efficacy of an anticancer agent, comprising administering to a subject in need thereof an effective amount of an adsorbent or an antibiotic-inactivating enzyme. | 2021-09-30 |
20210299171 | AQUEOUS SALINE COMPOSITION, PROCESS FOR THE PRODUCTION OF SAME, AND USE OF SAME - An aqueous saline composition comprising an organic film-protective and/or hyperosmotic compound, the method for obtaining the same, the use thereof as a drug, for example in the form of a spray, for prophylaxis, prevention or adjuvant treatment of ear, nose and throat -(ENT) conditions. | 2021-09-30 |
20210299172 | ENGINEERED PHAGOCYTIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF - The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid. | 2021-09-30 |
20210299173 | Enhancement of Production of NK Cells From Stem Cells - A composition and a method for generating clinically safe NK cells derived from non-fully differentiated stem cells are provided. The non-fully differentiated stem cells are co-cultured with endogenous NK cells isolated from adipocyte-containing tissue to generate a high percentage of clinically safe NK cells, where anti-tumor activity of the clinically safe NK cells in vitro is similar to that of endogenous NK cells. Optimized Production of the clinically safe autologous NK cells from stem cells provides platform for treating cancer patients by applying an effective adoptive immunotherapy ranging from the early to terminal stages. | 2021-09-30 |
20210299174 | CELL THERAPY - Disclosed herein are methods for providing cell therapy for treating or ameliorating a disease in an individual in need thereof, said methods comprising administering to said individual a cellular composition that comprises an engineered T-cell comprising: a first synthetic polynucleotide comprising a sequence encoding a CRISPR nuclease and an epigenetic enzyme or a functional portion thereof that modifies an epigenetic state; and a second synthetic polynucleotide comprising a sequence encoding a guide RNA (gRNA). Further disclosed herein are methods for reducing or preventing T-cell exhaustion in an individual in need thereof, said method comprising administering to said individual a cellular composition that comprises the engineered T-cell. | 2021-09-30 |
20210299175 | MODIFIED T LYMPHOCYTES - Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer. | 2021-09-30 |
20210299176 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND AUTOIMMUNE DISEASES - Described herein are compositions and methods for treating cancer and autoimmune diseases. | 2021-09-30 |
20210299177 | CHIMERIC RECEPTORS AND METHODS OF USE THEREOF - Provided herein are acute myeloid leukemia antigen targets for chimeric receptors and methods of using same. | 2021-09-30 |
20210299178 | METHODS OF USING DNASE1-LIKE 3 IN THERAPY - The present disclosure provides D1L3 enzymes having complete or partial C-terminal deletions of the basic domain (BD), which have substantially enhanced chromatin-degrading activity. In various aspects, the invention provides chromatinase enzyme therapy, which is optionally provided by delivering polynucleotides encoding chromatinases such as D1L3, or by delivering host cells expressing and secreting the same. | 2021-09-30 |
20210299179 | METHODS OF TREATING CONGENITAL HEMOPHILIA WITH ANTI-FIBRINOLYTIC LOADED PLATELETS - Provided herein are methods and compositions for treating congenital hemophilia with platelets and/or platelet derivatives. In some cases, the platelets and or platelet derivatives are loaded with an anti-fibrinolytic. | 2021-09-30 |
20210299180 | NOVEL ANUCLEATED CELLS AND USES THEREOF - Disclosed herein are non-naturally existing novel platelet variants or platelet like cells (PLCs), extracellular vesicles (EVs), and derivatives thereof. Composition comprising the same and methods for treatment or prevention of diseases or disorders therewith is also disclosed. | 2021-09-30 |
20210299181 | ANUCLEATED CELLS FOR THE TREATMENT OF DISEASES - The present disclosure takes advantage of non-naturally existing, novel, anucleated platelets or platelet-like cells or platelet variants (collectively referred to as PLCs) or derivatives thereof (i.e., genetically engineered), which share at least one common receptor, ligand or an antigen with endogenous cells that are targets for autoantibodies and effectuate their clearance. The present disclosure also takes advantage of viral adhesion or entry receptors or genetically engineered PLCs or derivatives thereof, which are engineered to express viral adhesion or entry receptors, that specifically binds to viral proteins on viruses or viral particles and effectuate their clearance. | 2021-09-30 |
20210299182 | METHODS AND SYSTEMS FOR PRODUCING AND ADMINISTERING ANTIVIRAL PLATELET THERAPY - This invention relates in general to the field of cell-therapy treatments and more particularly, but not by way of limitation, to systems and methods for administering personalized cell-therapy treatments intravenously. In various embodiments, the system may calculate an aspiration volume needed for centrifugation to achieve a concentrated target threshold dose of 2.5×10 | 2021-09-30 |
20210299183 | Treatment Of Vocal Cords With Autologous Dermal Fibroblast Formulation - Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL administered three times approximately three to six weeks apart, of cells at a concentration of from 1.0-2.0×10 | 2021-09-30 |
20210299184 | HUMAN UTERINE CERVICAL STEM CELL POPULATION AND USES THEREOF - The present invention relates to a method for isolating stem cells comprising preparing a cell suspension from uterine cervix tissue, to the stem cells isolated by said method, and to the conditioned medium obtained from the culture of said stem cells. The invention also encompasses the use of said stem cells or conditioned medium for treating or preventing cancer, precancerous lesions, inflammatory diseases, autoimmune diseases, chronic pathologies or infectious diseases, diseases associated to tissue loss, or for use in diagnostic, prognostic or treatment of fertility disorders, as well as for cosmetic treatment. | 2021-09-30 |
20210299185 | MAPC TREATMENT OF BRAIN INJURIES AND DISEASES - The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example. | 2021-09-30 |
20210299186 | VACCINATION WITH MICA/B ALPHA 3 DOMAIN FOR THE TREATMENT OF CANCER - The present invention provides compositions and methods for treating cancer in a subject by eliciting an immune response against a MIC alpha 3-domain polypeptide. | 2021-09-30 |
20210299187 | CANCER THERAPY - A non-viable, whole-cell | 2021-09-30 |
20210299188 | FECAL MICROBIOTA COMPOSITION FOR USE IN REDUCING TREATMENT-INDUCED INFLAMMATION - The invention relates to the use of fecal microbiota transplant for preventing and/or reducing systemic and gut treatment-induced inflammation in an individual in need thereof. | 2021-09-30 |
20210299189 | NOVEL CUTIBACTERIUM AVIDUM STRAIN, AND COMPOSITION FOR PREVENTING OR TREATING ATOPIC DERMATITIS, COMPRISING STRAIN OR CULTURED PRODUCT THEREOF - The present invention relates to | 2021-09-30 |
20210299190 | COMPOSITIONS COMPRISING BACTERIAL STRAINS - Provided are compositions comprising a bacterial strain of the genus | 2021-09-30 |
20210299191 | COMPOSITIONS AND METHODS - Provided are defined bacterial compositions for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for populating the gastrointestinal tract of a subject. Provided also are bacterial formulations for oral or gastric administration to a mammalian subject in an effective amount for prevention or treatment of a gastrointestinal disease, disorder or condition. | 2021-09-30 |
20210299192 | COMPOSITION FOR ANTI-OXIDATION, ORAL HEALTH, IMMUNITY REGULATION AND EXERCISE PROMOTION, AND USES THEREOF - A composition including a strain of | 2021-09-30 |
20210299193 | SYNBIOTIC COMPOSITION FOR IMPROVING IMMUNE RESPONSE AND ANTIOXIDANT CAPACITY DURING AGING AND A PROCESS FOR THE PREPARATION THEREOF - The present invention provides a synbiotic combination of i) a probiotic micro-organism comprising of a | 2021-09-30 |
20210299194 | COMPOSITION FOR PROMOTING ABSORPTION OF PHYTOCHEMICALS - Disclosed is a composition for promoting absorption of a poorly water-soluble phytochemical which can significantly improve the intake of a phytochemical into a body, especially a migration speed and/or a migration amount of the phytochemical into a blood. A polysaccharide-containing lactic acid bacterial product, which is produced by | 2021-09-30 |
20210299195 | VIRUS-LIKE PARTICLES WHICH CAN BE USED IN THE TREATMENT OF ALLERGIES - The invention relates to a virus-like particle comprising an allergen and an immunoregulatory molecule exposed on its surface. The invention also relates to the use of said particle in the treatment of an allergy. | 2021-09-30 |
20210299196 | PHARMACEUTICAL COMPOSITION BASED ON BACTERIOPHAGES AGAINST F. NUCLEATUM; USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH THIS PATHOGEN - A pharmaceutical composition comprising: a) an effective amount of one or more lytic bacteriophages specific against | 2021-09-30 |
20210299197 | ADMINISTERING COMPOSITIONS FOR IMPROVED IMMUNE SYSTEM FUNCTIONING - The present disclosure relates to methods of administering a composition to a patient, particularly in the form of a dietary supplement, which addresses immune system deficiencies and promotes healthy immune system functioning. The present disclosure also related to compositions and methods for improving or boosting immune system functioning. The present disclosure further provides novel compositions for balancing immune response in human subjects. | 2021-09-30 |
20210299198 | DIABETES-ALLEVIATING OR ANTIOXIDANT COMPOSITION COMPRISING YEAST EXTRACT AND METHOD FOR PREPARING YEAST EXTRACT - The present invention relates to a composition for ameliorating diabetes or enhancing antioxidant activity including a yeast extract and a method for preparing the yeast extract. | 2021-09-30 |
20210299199 | Neuron activator - The present disclosure provides a neuron activator that activates neurons. The neuron activator includes at least one selected from the group consisting of a dopamine production promotor that promotes dopamine production of the neurons, a neuron extension promotor that promotes extension of the neurons, and an amyloid β resistance enhancer that enhances resistance of the neurons against amyloid β. The neuron activator includes 6-methylsulfinylhexyl isothiocyanates or glycosides thereof, and at least one selected from the group consisting of unsaturated fatty acid and polyphenol. | 2021-09-30 |
20210299200 | Method of treating type 2 diabetic patients - The present disclosure provides a fermented papaya preparation comprising carbohydrate, protein lipid, potassium, and water, and methods of use thereof. | 2021-09-30 |
20210299201 | POLYPHENOL BLEND OF CURCUMIN EXTRACT AND POMEGRANATE EXTRACT AND METHODS OF IMPROVING IMMUNE RESPONSE - This invention is directed to compositions comprising curcumin extract and pomegranate extract, and methods of improving immune response with the compositions. The compositions may be administered as a prebiotic and/or a dietary supplement. | 2021-09-30 |
20210299202 | FORMULATION OF CANNABINOID COMPOUNDS - Cannabinoid compounds are formulated with a carbohydrate, including mono-, di-, oligo-, and polysaccharides into a stable, soluble and largely flavorless powder, sugar crystals or emulsions. | 2021-09-30 |
20210299203 | COMPOSITIONS COMPRISING CARUM CARVI AND ROSMARINUS OFFICINALIS EXTRACTS AND METHODS OF USING SAME - Provided are compositions comprising | 2021-09-30 |
20210299204 | Raelinh - JKL - L., or Bay Laurel, is an evergreen plant of the Lauraceae family native to the Mediterranean region and Southern Europe, widely used in herbal medicine. This is an original report on the antimicrobial bioactivity of Laurel and its regimental application effect as short-term remedy of tick-borne disease and symptoms. Utilizing brew method, loose parts of Laurel (as in leaves) were individually-measured for a 5-day regimen: Day 1—(0.5 gm.), Day 3—(1.0 gm), Day 5—(1.5 gm) with days 2, 4 in abstention; organ cleanser (as in liver) included as directed and increase in daily water intake (i.e. 160 lbs. body weight=80 oz. water) for flushing. Measure for rid of microbial endo-constituents: Jarisch-Herxheimer Reaction (JHR) observation. Day 1: Moderate/ Severe JHR; Day 2: Mild malaise; Day 3: Mild JHR; Days 4-5: no reaction. The results can be beneficial as alternative to long-term treatment with antibiotics. | 2021-09-30 |
20210299205 | WATER SOLUBLE TOMATO EXTRACT PROTECTS AGAINST ADVERSE EFFECTS OF AIR POLLUTION - The present invention relates to compositions comprising a water soluble tomato extract (WSTE) which may be used in maintaining cardiovascular health, lessening the risk of developing cardiovascular health problems, or reducing the likelihood of worsening an existing cardiovascular health problem in a subject exposed, or is at risk of exposure, to particulate air pollution. | 2021-09-30 |
20210299206 | VAGINAL CARE COMPOSITIONS - A natural vaginal care composition is provided. The natural composition includes a biobased vaginal care agent; a biobased thickener; and at least 60% water. The natural composition may optionally include a biobased preservative, a biobased emulsifier, and a biobased pH adjuster. The natural vaginal care composition is suitable for treating symptoms of vaginal atrophy and/or dryness. | 2021-09-30 |
20210299207 | SYSTEMS, METHODS, AND KITS FOR DIAGNOSTICS AND TREATMENT OF VIRAL RESPIRATORY INFECTION - Systems, methods, and kits for treating, preventing, and diagnosing viral infection using an androgen mediated pathway are described. Additionally, methods and kits for guiding treatment of viral respiratory disease are described by a method for testing for polymorphisms in the androgen receptor gene. Further, systems and methods for treatment of viral respiratory disease with various anti-androgens is detailed. Finally, systems, methods, and kits for treating, preventing, and diagnosing SARS-CoV-2 (COVID-19) are presented. | 2021-09-30 |
20210299208 | SYSTEMS, METHODS, AND KITS FOR DIAGNOSTICS AND TREATMENT OF VIRAL RESPIRATORY INFECTION - Systems, methods, and kits for treating, preventing, and diagnosing viral infection using an androgen mediated pathway are described. Additionally, methods and kits for guiding treatment of viral respiratory disease are described by a method for testing for polymorphisms in the androgen receptor gene. Further, systems and methods for treatment of viral respiratory disease with various anti-androgens is detailed. Finally, systems, methods, and kits for treating, preventing, and diagnosing SARS-CoV-2 (COVID-19) are presented. | 2021-09-30 |
20210299209 | SYSTEMS, METHODS, AND KITS FOR DIAGNOSTICS AND TREATMENT OF VIRAL RESPIRATORY INFECTION - Systems, methods, and kits for treating, preventing, and diagnosing viral infection using an androgen mediated pathway are described. Additionally, methods and kits for guiding treatment of viral respiratory disease are described by a method for testing for polymorphisms in the androgen receptor gene. Further, systems and methods for treatment of viral respiratory disease with various anti-androgens is detailed. Finally, systems, methods, and kits for treating, preventing, and diagnosing SARS-CoV-2 (COVID-19) are presented. | 2021-09-30 |
20210299210 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES - The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on an immune cell, conjugated via a linker to a second peptide ligand, which binds to a component present on a cancer cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer. | 2021-09-30 |
20210299211 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF - Aqueous pharmaceutical formulations, for parenteral administration, comprising peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof wherein the peptidomimetic macrocycle binds to MDM2 and/or MDMX proteins are disclosed. Also disclosed are methods of treating diseases and disorders using the aqueous pharmaceutical formulations disclosed herein. | 2021-09-30 |
20210299212 | BINDNG MOLECULES TO TUMOR ASSOCIATED MACROPHAGES AND METHODS OF USE - Provided herein are binding molecules to tumor associated macrophages and associated methods for the treatment and detection of cancer. | 2021-09-30 |
20210299213 | TREATMENT OF LOWER LIMB SPASTICITY - A method of treating lower limb spasticity in a subject, particularly one which is 18 years of age or under, comprising administering to the subject an effective amount of botulinum neurotoxin. A composition for use in treating lower limb spasticity in a patient comprising botulinum neurotoxin. A tool for use in determining the dosage amount of an active agent to be administered to a subject. | 2021-09-30 |
20210299214 | Use of PRG4 as an Anti-Inflammatory Agent - Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-κB translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens. | 2021-09-30 |
20210299215 | Use of Exosome-Based Delivery of NF-KB Inhibitors - The present disclosure relates to methods for treating acute kidney injury using exosome containing NF-κB inhibitors. The present disclosure relates to methods for treating diseases induced by sepsis using exosome containing NF-κB inhibitor. The present disclosure also is related to methods for treating respiratory diseases, such as viral respiratory diseases, using exosome containing NF-κB inhibitor. | 2021-09-30 |
20210299216 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION - In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof. | 2021-09-30 |
20210299217 | Universal Nanosponge for Treating Respiratory Viral Infection - A nanoparticle comprising an outer surface comprising a plasma membrane derived from a cell that can be infected with a respiratory virus, including a human lung epithelial cell expressing ACE-2 receptor. Methods of manufacture and use for preventing or treating viral infections, such as coronavirus infection in a subject in need are disclosed. | 2021-09-30 |